Digitisation | April 08, 2026
IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Subscribe To Our Newsletter & Stay Updated
